HelixNano

HelixNano, also known as Helix Nanotechnologies, is a biotechnology startup founded in 2013 by Hannu Rajaniemi and Carina Namih.

The company focuses on developing advanced mRNA platforms for various applications, including cancer vaccines and infectious disease treatments. With headquarters in Cambridge and Boston, Massachusetts, HelixNano operates at the intersection of synthetic biology, artificial intelligence, and mRNA delivery systems. The company offers an AI-driven mRNA platform that optimizes mRNA sequences for therapeutic targets. Their services include advanced mRNA delivery systems, custom nanomaterial synthesis, and computational wet-lab integration. HelixNano's product pipeline features innovative vaccines, such as a mutation-resistant COVID-19 vaccine and personalized cancer vaccines, alongside treatments for genetic diseases and transplant rejection. The company is backed by notable investors, including Y Combinator and Alumni Ventures, and aims to address significant challenges in healthcare and environmental sustainability through its technology.